Vivozon Pharmaceutical Resumes Trading After Stock Consolidation Completion: "Enhancing Corporate Value"

Bioson Pharmaceutical announced on the 10th that it has completed a stock consolidation and will resume stock trading.

Last month, Bioson Pharmaceutical decided on a 5-for-1 stock consolidation to stabilize the stock price and enhance corporate value by maintaining an appropriate number of circulating shares. With the completion of the stock consolidation, the total number of issued shares decreased from 241,058,577 to 48,211,715.

Bioson Pharmaceutical is a leading domestic company in the development of non-narcotic analgesics. Earlier this year, it completed the domestic Phase 3 clinical trial for its non-narcotic analgesic candidate, Opiranserin injection, and applied for a preliminary review of product approval with the Ministry of Food and Drug Safety in August. It is currently preparing for Phase 3 clinical trials for product approval with the U.S. Food and Drug Administration (FDA).

Additionally, to maximize corporate value, the company streamlined some business divisions such as cosmetics and light industry in July and is focusing on its core pharmaceutical business. As part of expanding its pharmaceutical business, it increased production capacity by expanding the vial production line.

A Bioson Pharmaceutical official stated, “The procedures for the domestic sales of Opiranserin, targeted for the second half of next year, are progressing smoothly. Since we restructured our business to focus on the pharmaceutical sector, we will strive to enhance corporate value through business achievements.”

Meanwhile, Bioson’s affiliate, Bioson, attended the ‘Bio Europe 2023’ conference held in Munich, Germany, from the 6th to the 8th. They strengthened their network for business cooperation by interacting with industry experts worldwide.

This content was produced with the assistance of AI translation services.